Home LiteratureArticle Details
PMID: 18820127 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

Molecular pharmacology ·Vol. 75 ·No. 1 ·2009-01-00 ·Pages 124-33

Tse AN, Sheikh TN, Alan H, Chou TC, Schwartz GK

Abstract

The G(2)/M cell cycle checkpoint is regulated by a multitude of signaling pathways after genotoxic stress. Herein, we report that treatment with the 90-kDa heat shock protein (Hsp90) molecular chaperone inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) selectively abrogates the G(2)/M checkpoint induced by 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan, in p53-null compared with p53-intact HCT116 colon cancer cells. The basis for this selectivity can be explained in part by the lack of p21 induction in p53-null cells. In accord with published results, we could show that treatment with 17AAG resulted in depletion of Chk1, a known Hsp90 client protein. In addition, we observed a time- and dose-dependent decrease in Wee1 kinase level, a negative regulator of mitosis, after 17AAG treatment in gastrointestinal cancer cells. Depletion of Wee1 protein preceded mitotic entry induced by 17AAG, and this decrease could be partially rescued by cotreatment with a proteasome inhibitor. Coimmunoprecipitation experiments showed that Hsp90 and Wee1 interacted in whole cells, and 17AAG treatment decreased the degradative half-life of Wee1, indicating that Wee1 is another Hsp90 client in mammalian cells. Knockdown of Chk1 and Wee1 by short interfering RNA each resulted in abrogation of the G(2)/M checkpoint induced by SN-38. The combination of SN-38 and 17AAG was shown to be synergistic in p53-null but not in parental HCT116 cells by median effect/combination index analysis. Taken together, 17AAG specifically inhibits the G(2)/M checkpoint in p53-defective cells by down-regulation of two critical checkpoint kinases, Chk1 and Wee1.

MeSH Terms
Apoptosis/drug effects Benzoquinones/pharmacology Camptothecin/analogs & derivatives,pharmacology Cell Cycle/drug effects,physiology Cell Cycle Proteins/metabolism Cell Survival/drug effects Checkpoint Kinase 1 DNA Topoisomerases, Type I/metabolism,pharmacology Dose-Response Relationship, Drug Drug Interactions G2 Phase Gene Expression Regulation, Neoplastic/drug effects HCT116 Cells HSP90 Heat-Shock Proteins/antagonists & inhibitors Humans Irinotecan Lactams, Macrocyclic/pharmacology Nuclear Proteins/metabolism Protein Kinases/metabolism Protein-Tyrosine Kinases/metabolism Time Factors Topoisomerase I Inhibitors Tumor Suppressor Protein p53/metabolism
Chemicals
Benzoquinones Cell Cycle Proteins HSP90 Heat-Shock Proteins Lactams, Macrocyclic Nuclear Proteins Topoisomerase I Inhibitors Tumor Suppressor Protein p53 tanespimycin Irinotecan Protein Kinases Protein-Tyrosine Kinases WEE1 protein, human CHEK1 protein, human Checkpoint Kinase 1 DNA Topoisomerases, Type I Camptothecin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Tse Archie N
Laboratory of New Drug Development, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. tsea@mskcc.org
Sheikh Tahir N
Alan Ho
Chou Ting-Chao
Schwartz Gary K
References (49)
49 references, click to expand
  1. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity.
    J Biol Chem. 1997 Aug 29;272(35):22300-6 PMID: 9268380
  2. The identification of Wos2, a p23 homologue that interacts with Wee1 and Cdc2 in the mitotic control of fission yeasts.
    Genetics. 1999 Dec;153(4):1561-72 PMID: 10581266
  3. Requirement for p53 and p21 to sustain G2 arrest after DNA damage.
    Science. 1998 Nov 20;282(5393):1497-501 PMID: 9822382
  4. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells.
    Clin Cancer Res. 1999 Jul;5(7):1876-83 PMID: 10430095
  5. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation.
    Mol Cell. 2005 Jan 7;17(1):37-48 PMID: 15629715
  6. Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones.
    J Biol Chem. 2006 Feb 3;281(5):2989-98 PMID: 16330544
  7. Hsp90: a novel target for cancer therapy.
    Curr Top Med Chem. 2006;6(11):1205-14 PMID: 16842157
  8. Chaperoning steroid hormone action.
    Trends Endocrinol Metab. 2006 Aug;17(6):229-35 PMID: 16806964
  9. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Pharmacol Rev. 2006 Sep;58(3):621-81 PMID: 16968952
  10. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
    Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):591-602 PMID: 17255282
  11. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
    Cancer Cell. 2007 Feb;11(2):175-89 PMID: 17292828
  12. Targeting checkpoint kinase 1 in cancer therapeutics.
    Clin Cancer Res. 2007 Apr 1;13(7):1955-60 PMID: 17404075
  13. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.
    Oncogene. 2008 May 15;27(22):3091-101 PMID: 18071310
  14. DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2.
    Cell Cycle. 2008 Jun 1;7(11):1668-77 PMID: 18469532
  15. Temperature-sensitive ZAP70 mutants degrading through a proteasome-independent pathway. Restoration of a kinase domain mutant by Cdc37.
    J Biol Chem. 1999 Dec 3;274(49):34515-8 PMID: 10574909
  16. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.
    J Natl Cancer Inst. 1996 Jul 17;88(14):956-65 PMID: 8667426
  17. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.
    Genes Dev. 2000 Feb 1;14(3):278-88 PMID: 10673500
  18. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01.
    J Biol Chem. 2000 Feb 25;275(8):5600-5 PMID: 10681541
  19. Rapid destruction of human Cdc25A in response to DNA damage.
    Science. 2000 May 26;288(5470):1425-9 PMID: 10827953
  20. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.
    Genes Dev. 2000 Jun 15;14(12):1448-59 PMID: 10859164
  21. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
    Cancer Res. 2000 Jul 15;60(14):3940-6 PMID: 10919672
  22. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins.
    Mol Biol Cell. 2001 Mar;12(3):551-63 PMID: 11251070
  23. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1.
    Eur J Biochem. 2001 Apr;268(8):2281-9 PMID: 11298745
  24. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
    Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8379-83 PMID: 8710879
  25. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation.
    EMBO J. 1997 Feb 3;16(3):545-54 PMID: 9034337
  26. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase.
    J Biol Chem. 2008 Jul 11;283(28):19322-8 PMID: 18480045
  27. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells.
    Oncogene. 2008 Sep 18;27(42):5567-77 PMID: 18504430
  28. Regulation of the G2/M transition by p53.
    Oncogene. 2001 Apr 5;20(15):1803-15 PMID: 11313928
  29. 14-3-3 binding regulates catalytic activity of human Wee1 kinase.
    Cell Growth Differ. 2001 Dec;12(12):581-9 PMID: 11751453
  30. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
    Clin Cancer Res. 2001 Dec;7(12):4209-19 PMID: 11751522
  31. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints.
    Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14795-800 PMID: 12399544
  32. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects.
    EMBO J. 2003 Feb 3;22(3):713-23 PMID: 12554671
  33. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A.
    Cancer Cell. 2003 Mar;3(3):247-58 PMID: 12676583
  34. Questioning the role of checkpoint kinase 2 in the p53 DNA damage response.
    J Biol Chem. 2003 Jun 6;278(23):20480-9 PMID: 12654916
  35. The Chk2 tumor suppressor is not required for p53 responses in human cancer cells.
    J Biol Chem. 2003 Jun 6;278(23):20475-9 PMID: 12654917
  36. Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.
    J Biol Chem. 2003 Jun 13;278(24):21767-73 PMID: 12676925
  37. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
    J Biol Chem. 2003 Dec 26;278(52):52572-7 PMID: 14570880
  38. Targeting the checkpoint kinases: chemosensitization versus chemoprotection.
    Nat Rev Cancer. 2004 Mar;4(3):216-25 PMID: 14993903
  39. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
    Cancer Lett. 2004 Apr 8;206(2):149-57 PMID: 15013520
  40. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP.
    Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4419-24 PMID: 15070733
  41. Heat shock protein 90 regulates the metaphase-anaphase transition in a polo-like kinase-dependent manner.
    Cancer Res. 2004 Aug 1;64(15):5106-12 PMID: 15289312
  42. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
    Cancer Res. 2004 Sep 15;64(18):6635-44 PMID: 15374978
  43. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase.
    Science. 1992 Sep 25;257(5078):1955-7 PMID: 1384126
  44. A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90.
    EMBO J. 1994 Dec 15;13(24):6099-106 PMID: 7813446
  45. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells.
    Cancer Res. 1995 Apr 15;55(8):1639-42 PMID: 7712467
  46. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay.
    Cancer Res. 1995 Apr 15;55(8):1643-8 PMID: 7712468
  47. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle.
    EMBO J. 1995 May 1;14(9):1878-91 PMID: 7743995
  48. Geldanamycin selectively destabilizes and conformationally alters mutated p53.
    Oncogene. 1995 Sep 7;11(5):933-9 PMID: 7675452
  49. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor.
    Clin Cancer Res. 1996 May;2(5):791-7 PMID: 9816232
Article Info
Journal
Molecular pharmacology
Abbr.
Mol Pharmacol
ISSN
1521-0111
Published
2009-01-00
Epub
2008-00-26
Pages
124-33
Language
English
Region
United States
NLM ID
0035623
PMCID
PMC2685054
Subset
IM
Grants
PHS HHS · K08 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com